<DOC>
	<DOCNO>NCT02204241</DOCNO>
	<brief_summary>This protocol phase I/II multicenter study design ass safety efficacy propose combination up-front treatment elderly Multiple Myeloma ( MM ) patient .</brief_summary>
	<brief_title>Study Carfilzomib , Cyclophosphamide Dexamethasone Newly Diagnosed Multiple Myeloma Patients</brief_title>
	<detailed_description>Treatment schedule 9 cycle induction : Phase I : In phase I portion study , follow dose level carfilzomib study fixed dos dexamethasone cyclophosphamide define maximum tolerate dose ( MTD ) : Level-1 : 1 . Carfilzomib give 20 mg/m2 IV daily day 1-2 Cycle 1 follow 36 mg/m2 day 8-9 , 15-16 , Cycle 1 , subsequent dose 36 mg/m2 IV daily day 1-2 , 8-9 , 15-16 . 2 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 3 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9 , 15-16 , 22-23 Level 0 : 1 . Carfilzomib give 20 mg/m2 IV daily day 1-2 Cycle 1 follow 45 mg/m2 day 8-9 , 15-16 , Cycle 1 , subsequent dose 45 mg/m2 IV daily day 1-2 , 8-9 , 15-16 . 2 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 3 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9 , 15-16 , 22-23 Level +1 : 1 . Carfilzomib give 20 mg/m2 IV daily day 1-2 Cycle 1 follow 56 mg/m2 day 8-9 , 15-16 , Cycle 1 , subsequent dose 56 mg/m2 IV daily day 1-2 , 8-9 , 15-16 . 2 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 3 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9 , 15-16 , 22-23 Level +2 : 1 . Carfilzomib give 20 mg/m2 IV daily day 1-2 Cycle 1 follow 36 mg/m2 day 8-9 , 15-16 , Cycle 1 , subsequent dose 70 mg/m2 IV daily day 1-2 , 8-9 , 15-16 . 2 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 3 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9 , 15-16 , 22-23 Patient observe end second cycle therapy assessment side effect observation DLTs . Dose escalation proceed follow : - 3 patient enter dose level 0 - If 0/3 patient experience DLT , dose escalation continue - If 1/3 patient experience DLT , 3 additional patient add cohort ( max 6 ) - If patient experience DLT ( 1/6 ) dose escalation continue - If 2/6 patient experience DLT , MTD exceed MTD previous dose &lt; 2/6 experience DLT - If 2/3 patient experience DLT give dose , MTD exceed MTD precede dose &lt; 2/6 ( 1/3 ) patient experience DLT . Phase II : The dose use treat patient phase II MTD define phase I study . Treatment schedule maintenance progression intolerance : Carfilzomib MTD define phase I study IV daily day 1-2 , 15-16 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient legally consent age define local regulation . Patient age ≥ 65 year age ineligible autologous stem cell transplantation . Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Women childbearing potential must negative serum pregnancy test within 7 day prior study drug administration negative urine pregnancy test within 3 day prior first study drug administration . Women childbearing potential male subject sexullay active WOCBP must agree use 2 highly effective method contraception study 30 day follow last dose study treatment include male condom . Patient newly diagnose MM patient . Patient measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , ≥ 0.5 g/dL Mprotein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . For patient oligo nonsecretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) abnormal free light chain ratio ( n.v. : 0.261.65 ) . We anticipate less 10 % patient admit study oligo nonsecretory MM free light chain order maximize interpretation benefit result . Patient Karnofsky performance status ≥60 % . Patient lifeexpectancy &gt; 3 month . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 , study drug administration ) : Platelet count ≥50 x 109/L ( ≥30 x 109 /L myeloma involvement bone marrow &gt; 50 % ) within 14 day prior drug administration . Absolute neutrophil count ( ANC ) ≥ 1 x 109/L without use growth factor . Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) Alanine transaminase ( ALT ) : ≤ 3 x ULN . Total bilirubin : ≤ 2 x ULN . Calculated measured creatinine clearance : ≥ 15 mL/minute LVEF ≥40 % . 2D transthoracic ECHO prefer method evaluation . Multigated Acquisition Scan acceptable ECHO available Patients nonsecretory MM , unless serum free light chain present ratio abnormal . Women pregnant and/or breast feeding . Patient active infectious hepatitis type B C HIV . Pulmonary Hypertension . QTc Interval ≥ 450 msec . Uncontrolled Atrial Fibrillation/Flutter . History Torsade de pointe , Ventricular Tachycardia , Ventricular Fibrillation . Uncontrolled Infection . Patients myocardial infarction unstable angina ≤ 4 month clinically significant heart disease ( e.g. , CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . Patient peripheral neuropathy &gt; CTCAE grade 2 . Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) . Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior baseline . Patient clinically significant illness would , investigator 's opinion , increase patient 's risk toxicity . Patients prior malignancy within last 5 year ( except basal squamous cell carcinoma , situ cancer cervix breast , localized prostate cancer Gleason score &lt; 7 stable PSA ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>CCyd</keyword>
</DOC>